Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600–mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO)

Acalabrutinib vs Rituximab Plus Idelalisib or Bendamustine by Investigator Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Adverse Event Management Strategies and Interventions for Treatment of Patients With HR+, HER2– Advanced Breast Cancer With Alpelisib Plus Fulvestrant

Efficacy/Safety of Talazoparib or Physician’s Choice of Therapy in US Patients With HER2-negative Germline BRCA1/2-mutated Locally Advanced/Metastatic Breast Cancer (EMBRACA)

Nursing Best Practices for Moxetumomab Pasudotox-tdfk, a New Treatment for Hairy Cell Leukemia

Nursing Experience in Patients Receiving Long-Term Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Final Analysis Results From Phase 3 RESONATE Study

Oncology Nursing Experience in Phase 3 iLLUMINATE: First-Line Ibrutinib-Obinutuzumab Versus Chlorambucil-Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)